Bong AB, Bonnekoh B, Franke I, Schön MP, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology. 2002;205(2):135–8.

Article  CAS  PubMed  Google Scholar 

Redondo P, de Olmo J, de Cerio AL-D, Inoges S, Marquina M, Melero I, et al. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol. 2007;127(7):1673–80.

Article  CAS  PubMed  Google Scholar 

Van Zeijl M, Van Den Eertwegh A, Haanen J, Wouters M. (Neo) adjuvant systemic therapy for melanoma. Eur J Surg Oncol (EJSO). 2017;43(3):534–43.

Article  PubMed  Google Scholar 

Austin E, Mamalis A, Ho D, Jagdeo J. Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: a systematic review. Arch Dermatol Res. 2017;309(4):229–42.

Article  PubMed  Google Scholar 

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer JR, Tykodi SS, Chow LQ, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793.

Article  CAS  PubMed  Google Scholar 

Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46.

Article  CAS  PubMed  Google Scholar 

Darvin P, Toor SM, Nair VS, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–11.

Article  PubMed  Google Scholar 

Schmid D, Park CG, Hartl CA, Subedi N, Cartwright AN, Puerto RB, et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun. 2017;8(1):1747.

Article  PubMed  PubMed Central  Google Scholar 

Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, et al. Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma. J Clin Investig. 2016;126(9):3447–52.

Article  PubMed  PubMed Central  Google Scholar 

Guilloux Y, Viret C, Gervois N, Dréan EL, Pandolfino M-C, Diez E, et al. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur J Immunol. 1994;24(9):1966–73.

Article  CAS  PubMed  Google Scholar 

Viret C, Gervois N, Guilloux Y, Le Dréan E, Diez E, Jotereau F, et al. T cell activation by antigens on human melanoma cells—co-stimulation by B7–1 is neither sufficient nor necessary to stimulate IL-2 secretion by melanoma-specific T cell clones in vitro. Int Immunol. 1995;7(10):1535–43.

Article  CAS  PubMed  Google Scholar 

Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541(7637):321–30.

Article  CAS  PubMed  Google Scholar 

Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002;218(1–2):74–86.

Article  CAS  PubMed  Google Scholar 

Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, Garra A, Vicari A, et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med. 2005;201(7):1157.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, et al. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Ann Oncol. 2018;29(11):2163–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Phuengkham H, Song C, Lim YT. A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy. Adv Mater. 2019;31(42):1903242.

Article  CAS  Google Scholar 

De Vrieze J, Louage B, Deswarte K, Zhong Z, De Coen R, Van Herck S, et al. Potent lymphatic translocation and spatial control over innate immune activation by polymer–lipid amphiphile conjugates of small-molecule TLR7/8 agonists. Angew Chem Int Ed. 2019;58(43):15390–5.

Article  Google Scholar 

Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126(12):1452–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Festenstein H, Garrido F. Tumour immunology: MHC antigens and malignancy. Nature. 1986;322(6079):502–3.

Article  CAS  PubMed  Google Scholar 

Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today. 1993;14(10):491–9.

Article  CAS  PubMed  Google Scholar 

Manome Y, Suzuki D, Mochizuki A, Saito E, Sasa K, Yoshimura K, et al. The inhibition of malignant melanoma cell invasion of bone by the TLR7 agonist R848 is dependent upon pro-inflammatory cytokines produced by bone marrow macrophages. Oncotarget. 2018;9(52):29934.

Article  PubMed  PubMed Central  Google Scholar 

Caisová V, Vieru A, Kumžáková Z, Glaserová S, Husníková H, Vácová N, et al. Innate immunity based cancer immunotherapy: B16–F10 murine melanoma model. BMC Cancer. 2016;16(1):940.

Article  PubMed  PubMed Central  Google Scholar 

Sabado RL, Pavlick A, Gnjatic S, Cruz C, Vengco I, Hasan F, et al. Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. J Immunother Cancer. 2013;1(1):P272.

Article  PubMed Central  Google Scholar 

Royal RE, Vence LM, Wray T, Cormier JN, Lee JE, Gershenwald JE, et al. A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application. Am Soc Clin Oncol. 2017;35:9582–9582.

Article  Google Scholar 

Vinod N, Hwang D, Azam SH, Van Swearingen AE, Wayne E, Fussell SC, et al. High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. Sci Adv. 2020;6(25):eaba5542.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun J, Liu Z, Yao H, Zhang H, Zheng M, Shen N, et al. Azide‐masked resiquimod activated by hypoxia for selective tumor therapy. Adv Mater 2023; Accepted Author Manuscript 2207733. https://doi.org/10.1002/adma.202207733

Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24:148–54.

Article  CAS  PubMed  Google Scholar 

El-Khattouti A, Selimovic D, Hannig M, Taylor EB, AbdElmageed ZY, Hassan SY, et al. Imiquimod-induced apoptosis of melanoma cells is mediated by ER stress-dependent Noxa induction and enhanced by NF-κB inhibition. J Cell Mol Med. 2016;20(2):266–86.

Article  CAS  PubMed  Google Scholar 

Kalb ML, Glaser A, Stary G, Koszik F, Stingl G. TRAIL+ human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod-and IFN-α–mediated antitumor reactivity. J Immunol. 2012;188(4):1583–91.

Article  CAS  PubMed  Google Scholar 

Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2002;2:1.

PubMed  Google Scholar 

McCarter MD, Baumgartner J, Escobar GA, Richter D, Lewis K, Robinson W, et al. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007;14(10):2854–60.

Article  PubMed  Google Scholar 

Kleffel S, Posch C, Barthel Steven R, Mueller H, Schlapbach C, Guenova E, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162(6):1242–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sallam MA, Shields CW IV, Prakash S, Kim J, Pan DC, Mitragotri S. A dual macrophage polarizer conjugate for synergistic melanoma therapy. J Control Release. 2021;335:333–44.

Article  CAS  PubMed  Google Scholar 

Fernández I, Peña A, Del Teso N, Pérez V, Rodríguez-Cuesta J. Clinical biochemistry parameters in C57BL/6J mice after blood collection from the submandibular vein and retroorbital plexus. J Am Assoc Lab Anim Sci. 2010;49(2):202–6.